NASDAQ · Biotechnology

CCCC (CCCC) Stock

$3.87 +4.31% NASDAQ: CCCC Healthcare

Valuation

MetricValue
Price$3.87
Market Cap$427.89M
P/E Ratio-2.54
P/B Ratio1.04
P/S Ratio7.76
EPS (TTM)$-1.27
52-Week High$5.08
52-Week Low$1.36
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-40.86%
ROA-29.25%
ROCE-40.47%
Gross Margin-288.89%
Operating Margin-288.89%
Net Margin-2.98%
Debt/Equity0.25
Current Ratio7.82

Annual Financials (USD)

Metric20212022202320242025
Revenue$46.0M$31.0M$21.0M$36.0M$36.0M
Operating Profit$-82.0M$-130.0M$-139.0M$-120.0M$-104.0M
Net Profit$-84.0M$-128.0M$-132.0M$-105.0M$-105.0M
EPS$-1.82$-2.62$-2.67$-1.52$-1.27
Op Margin-179.4%-416.6%-669.8%-336.1%-290.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$507.0M$431.0M$376.0M$350.0M$359.0M
Total Liabilities$117.0M$142.0M$130.0M$134.0M$102.0M
Cash$76.0M$30.0M$127.0M$55.0M$75.0M
Borrowings$43.0M$87.0M$71.0M$66.0M$60.0M

Latest News

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year? Zacks · Jul 7, 2026 C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know Zacks · Jul 3, 2026 C4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher? Insider Monkey · Jul 3, 2026 Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year? Zacks · Jun 18, 2026 C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D MT Newswires · Jun 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-87.0M$-106.0M$-107.0M$-65.0M$-99.0M
Investing Cash Flow$-191.0M$53.0M$157.0M$-51.0M$-9.0M
Financing Cash Flow$2.0M$0$0$1.0M$0
Net Cash Flow$-105.0M$-46.0M$97.0M$-71.0M$19.0M
Free Cash Flow$-88.0M$-111.0M$-109.0M$-65.0M$-99.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-35.51%
Quick Ratio9.00
Interest Coverage—
Return 1Y50.83%
Return 3Y-2.14%
Return 5Y-89.79%

Ownership

Insiders Held0.93%
Institutions Held85.31%
Institutions Float Held86.11%
Institutional HolderSharesReport Date
Morgan Stanley9,072,4002026-03-31
RA Capital Management, L.P.8,000,0002026-03-31
Bain Capital Life Sciences Investors, LLC7,171,9102026-03-31
Lynx1 Capital Management Lp6,998,9022026-03-31
Vanguard Capital Management LLC3,861,8522026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARMP $5.28 -4.17% -1.03 $193.83M 0.00%
CDXS $1.51 -11.18% -5.06 $162.42M 0.00%
CYBNCybin Inc. $8.28 +1.22% -1.67 $413.02M 0.00%
IMDX $3.84 -2.04% -2.83 $123.99M 0.00%
MIST $1.14 -1.72% -2.00 $141.93M 0.00%

About CCCC

CCCC is led by CEO Andrew J. Hirsch, employs 110 people, headquartered in US, publicly traded since 2020.

CCCC stock trades at $3.87 with a market capitalization of $427.89M. The stock is valued at a price-to-earnings (P/E) ratio of -2.54, price-to-book of 1.04, price-to-sales of 7.76. Over the past 52 weeks the stock has ranged between $1.36 and $5.08, and currently trades 23.8% below its 52-week high.

On profitability, CCCC generates a return on equity (ROE) of -40.86%, return on capital employed of -40.47%, an operating margin of -288.89%, a net profit margin of -2.98%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides